PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPacritinib
Pacritinib
Vonjo (pacritinib) is a small molecule pharmaceutical. Pacritinib was first approved as Vonjo on 2022-02-28. It is used to treat primary myelofibrosis in the USA. The pharmaceutical is active against tyrosine-protein kinase JAK2. In addition, it is known to target tyrosine-protein kinase JAK1, receptor-type tyrosine-protein kinase FLT3, and tyrosine-protein kinase JAK3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
Trade Name
FDA
EMA
Vonjo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pacritinib citrate
Tradename
Company
Number
Date
Products
VONJOCTI BiopharmaN-208712 RX2022-02-28
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
vonjoNew Drug Application2024-11-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
primary myelofibrosisD055728D47.4
Agency Specific
FDA
EMA
Expiration
Code
PACRITINIB CITRATE, VONJO, CTI BIOPHARMA CORP
2029-02-28ODE-397
2027-02-28NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Pacritinib Citrate, Vonjo, Cti Biopharma Corp
89808732030-03-25DS, DPU-3331, U-3332
81536322029-01-17DS, DPU-3331, U-3332
95739642028-05-05U-3331, U-3332
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
L01EJ: Janus-associated kinase (jak) inhibitors
L01EJ03: Pacritinib
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728D47.43328
Polycythemia veraD011087D45224
Essential thrombocythemiaD013920D47.3123
ThrombocytosisD013922D75.83123
PolycythemiaD011086EFO_0005804D75.1123
ThrombocytopeniaD013921HP_0001873D69.611
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C95213
Myelodysplastic syndromesD009190D46112
PreleukemiaD011289112
NeoplasmsD009369C80112
Myeloproliferative disordersD009196D47.1112
Graft vs host diseaseD006086D89.81111
Covid-19D000086382U07.111
Colorectal neoplasmsD01517911
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients55
Drug interactionsD00434722
Myeloid leukemia acuteD015470C92.011
Myeloid leukemiaD007951C9211
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034011
Myelomonocytic leukemia chronicD015477C93.111
Myelomonocytic leukemia acuteD015479C92.511
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.211
Myelomonocytic leukemia juvenileD054429C93.311
SyndromeD01357711
Show 3 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePacritinib
INNpacritinib
Description
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Identifiers
PDB
CAS-ID937272-79-2
RxCUI
ChEMBL IDCHEMBL2035187
ChEBI ID
PubChem CID46216796
DrugBankDB11697
UNII IDG22N65IL3O (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
JAK3
JAK3
NQO2
NQO2
Organism
Homo sapiens
Gene name
JAK3
Gene synonyms
NCBI Gene ID
Protein name
tyrosine-protein kinase JAK3
Protein synonyms
JAK-3, Janus kinase 3, Janus kinase 3 (a protein tyrosine kinase, leukocyte), L-JAK, Leukocyte janus kinase
Uniprot ID
Mouse ortholog
Jak3 (16453)
tyrosine-protein kinase JAK3 (Q62137)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,085 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,280 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use